Posted inNeurology Oral AR1001 Hits Primary Endpoint in Prespecified Early AD Monotherapy Cohort at CTAD 2026 Posted by By Zhang Paul 11/21/2026 BOSTON — Topline 52-week results from the global Phase 3 POLARIS-AD trial presented at the…